3 results
To assess whether a rivaroxaban-based anticoagulation strategy, following successful TAVR, compared to an antiplatelet-based strategy, is superior in reducing death or first thromboembolic events (DTE).To assess the primary bleeding events (PBE) of…
The aim of this study is to evaluate whether the MyTAP can be used as a screening tool to predict treatment success with MAD therapy. This will be evaluated during a 3 month follow-up of the therapy.Secondly, we want to compare the patient…
Primary Objectives:Our primary objectives are:1. To evaluate the safety, tolerability and pharmacokinetics of intravenously (IV) administered M6229 in critically ill patients with sepsis with specific attention to anti-coagulation effects (based on…